CCND1 and breast cancer: Moreover, a phase II window-of-opportunity trial has shown that high-dose atorvastatin (80 mg/day) induced anti-proliferative effects in breast cancer through cell cycle regulation via cyclin D1 and p27 (188) (Table 1).